IPIX

Innovation Pharmaceuticals Inc. [IPIX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IPIX Stock Summary

In the News

IPIX Financial details

Company Rating
-
Market Cap
6.68M
Income
-1.96M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-1.5
Forward P/E
-
PEG
0.2
P/S
-
P/B
2.54
P/C
-
P/FCF
-1.43
Quick Ratio
0.17
Current Ratio
0.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-55.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-200%
EPS Q/Q
-76.92%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-29%
ROE
-87%
ROC
-1.19%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-2%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.0E-4-0.023
52W High
-
52W Low
-
RSI
48.28
Rel Volume
0.02
Avg Volume
724.79K
Volume
15.5K
Perf Week
-
Perf Month
0%
Perf Quarter
-75%
Perf Half Y
-80%
-
-
-
-
Beta
-0.213
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0001
Change
0%

Something similar

Top by Market Cap
BRK-B
VOO
1YD.DE
MIX.JO
VFINX
Same Sector
CRDF
JSPR
2784.T
KIMS.NS
UPC
Same Price Range
RENO
GXXM
MGTI
GEECF
QKLS
Similar Market Cap
MBRX
MNTS
DBGR
ALPAU.PA
PRR.CN

Company Profile

Healthcare Biotechnology
  • Volume Average 724.79K
  • Market Capitalization 6.68M
  • Employee 4
  • CEO Mr. Leo Ehrlich CPA
  • Headquarters Wakefield,MA,US
  • IPO Date 2007-05-04
  • Website https://www.ipharminc.com

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.